119 related articles for article (PubMed ID: 11551406)
1. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Tatum A; Herndon JE; Box J; Memoli V; Green MR; Kern JA
Lung Cancer; 2001; 33(2-3):115-23. PubMed ID: 11551406
[TBL] [Abstract][Full Text] [Related]
2. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Kern JA; Herndon JE; Tatum A; Brisson ML; Memoli V; Sugarbaker D; Skarin AT; Kreisman H; Green MR
Lung Cancer; 1998 Sep; 21(3):203-11. PubMed ID: 9857998
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
Gajra A; Tatum AH; Newman N; Gamble GP; Lichtenstein S; Rooney MT; Graziano SL
Lung Cancer; 2002 May; 36(2):159-65. PubMed ID: 11955650
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
7. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
[TBL] [Abstract][Full Text] [Related]
8. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.
Linnoila RI; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):367S-371S. PubMed ID: 7988266
[TBL] [Abstract][Full Text] [Related]
9. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
10. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
[TBL] [Abstract][Full Text] [Related]
11. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
12. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.
Brooks KR; To K; Joshi MB; Conlon DH; Herndon JE; D'Amico TA; Harpole DH
Ann Thorac Surg; 2003 Jul; 76(1):187-93; discussion 193. PubMed ID: 12842538
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
[TBL] [Abstract][Full Text] [Related]
14. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
[TBL] [Abstract][Full Text] [Related]
15. [Neuroendocrine differentiation as a survival prognostic factor in advanced non-small cell lung cancer].
Petrović M; Tomić I; Ilić S
Vojnosanit Pregl; 2007 Aug; 64(8):525-9. PubMed ID: 17874719
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis.
Hilbe W; Dirnhofer S; Oberwasserlechner F; Eisterer W; Ammann K; Schmid T; Hilbe G; Thaler J; Wöll E
J Clin Pathol; 2003 Oct; 56(10):736-41. PubMed ID: 14514775
[TBL] [Abstract][Full Text] [Related]
17. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.
Linnoila RI; Mulshine JL; Steinberg SM; Funa K; Matthews MJ; Cotelingam JD; Gazdar AF
Am J Clin Pathol; 1988 Dec; 90(6):641-52. PubMed ID: 2848408
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy.
Tanaka Y; Ogawa H; Uchino K; Ohbayashi C; Maniwa Y; Nishio W; Nakao A; Yoshimura M
J Thorac Cardiovasc Surg; 2013 Mar; 145(3):839-46. PubMed ID: 22498090
[TBL] [Abstract][Full Text] [Related]
20. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]